CARCINOMA, NON-SMALL-CELL LUNG

This study is testing if adding an immunotherapy drug (nivolumab) to standard chemotherapy, both before and after surgery, is better at preventing cancer from returning in people with early-stage, operable lung cancer. About 461 participants with stage II or III non-small cell lu…

This study tested whether a drug called durvalumab could help control Stage III non-small cell lung cancer that cannot be surgically removed. About 400 patients who had completed chemoradiation without their cancer getting worse received either durvalumab or a placebo. The main g…

This study is testing an experimental drug called Dato-DXd in Chinese patients with advanced non-small cell lung cancer or triple-negative breast cancer that has stopped responding to standard treatments. The drug is given as an IV infusion every three weeks to see if it can shri…

This study is comparing two drugs, repotrectinib and crizotinib, for people with advanced non-small cell lung cancer that has a specific genetic marker called ROS1. The main goal is to see which drug is better at delaying cancer growth and is safer for patients. It is for people …

This study is testing whether adding very high doses of vitamin C (given through an IV) to standard chemotherapy and radiation treatment helps people with non-small cell lung cancer. All 43 participants will receive the vitamin C infusion along with their usual cancer therapy. Re…

This study is testing whether an experimental drug called tisotumab vedotin, given alone or with other cancer drugs, can help control advanced solid tumors. It enrolled 352 people with advanced colorectal, lung, pancreatic, or head and neck cancers that had stopped responding to …

This study is testing the safety and effectiveness of combining two drugs, amivantamab and cetrelimab, for people with advanced non-small cell lung cancer that has spread. The first part finds the best dose, and the second part checks how well that dose shrinks tumors in specific…

This early-stage study is testing the safety and effectiveness of new drug combinations for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an EGFR mutation. The trial is testing a pill called lazertinib alone and combined with an…

This study tested whether a newer drug called lorlatinib works better than the standard drug crizotinib for people with advanced non-small cell lung cancer that has a specific genetic change (ALK-positive). The trial involved 296 adults who had not received any prior treatment fo…

This study looks back at medical records to understand how well the oral medication lorlatinib works for people with a specific type of advanced lung cancer (ROS1-positive NSCLC) that has stopped responding to other treatments. Researchers are analyzing data from 35 patients who …

This early-stage study is testing a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find the safest dose and understand side effects in 65 participants with specific cancers includin…

This study tested an oral medication called TAK-788 (mobocertinib) for adults with non-small cell lung cancer (NSCLC). The main goals were to find a safe and effective dose, understand how the body processes the drug, and see if it can shrink tumors, especially in people whose ca…

This study is for people with advanced non-small cell lung cancer whose disease progressed after standard immunotherapy. Researchers want to see if adding a different immunotherapy drug (ipilimumab) and targeted radiation to a few tumors can help patients respond again to the ori…

This is an early safety study for a new oral medicine, PF-07985045, designed for people with advanced solid tumors that have a specific KRAS gene mutation. The study will test the medicine by itself and combined with other cancer treatments to find a safe dose and see how the bod…

This early-stage study is testing the safety and effectiveness of new two-drug combinations for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to previous treatments. The trial enrolled 43 participants…

This early-stage study is testing a new drug called AZD7789 in people with advanced lung or stomach cancers that have spread and stopped responding to standard immunotherapy. The main goals are to find a safe dose and see if the drug shows any signs of shrinking tumors. The drug …

This study tests a decision-making tool designed to help doctors and patients with advanced lung cancer decide when to continue or stop aggressive treatments near the end of life. It compares usual care to using a structured checklist that guides conversations about treatment goa…

This large, late-stage study is testing if adding a drug to standard radiation treatment can better control early-stage lung cancer that cannot be surgically removed. For most participants, the drug is an immunotherapy (durvalumab) given alongside precise radiation. For a smaller…

This study tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy works better than chemotherapy alone for people with advanced lung cancer. It's for patients whose cancer has specific genetic changes and stopped responding to their previous…

This large, late-stage study is comparing an experimental targeted drug called sigvotatug vedotin against standard chemotherapy (docetaxel) for adults with advanced non-small cell lung cancer that has worsened after initial treatment. The trial aims to see if the new drug helps p…

This study is testing three different medications to see if they can prevent or lessen severe reactions that some patients experience during their first infusion of a targeted lung cancer drug called amivantamab. It involves 68 adults with a specific type of advanced lung cancer …

This study aimed to test a three-part treatment plan for people with advanced, inoperable non-small cell lung cancer. The plan involved chemotherapy before, during, and after a course of radiation therapy to see if this aggressive combination was feasible and effective. The trial…

This early-stage study is testing an oral medication called LOXO-260 for people with advanced cancers driven by specific changes in the RET gene. The goal is to find a safe dose and see if it can help control tumors that have stopped responding to other similar targeted drugs. Th…

This study is testing whether the drug selpercatinib can delay or prevent cancer from returning in people with early-stage non-small cell lung cancer who have already had surgery or radiation treatment. Participants will receive either the active drug or a placebo for up to three…

This is an early-stage study testing a new drug called DKY709, both alone and combined with another drug (PDR001), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find safe doses and understand side effects. Researcher…

This study is testing whether adding a new targeted drug called amivantamab to standard chemotherapy works better than chemotherapy alone for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The main goal is to see if th…

This large, late-stage trial is testing if adding a newer drug (sacituzumab govitecan) to a standard immunotherapy (pembrolizumab) works better than the immunotherapy alone for adults with a specific type of advanced lung cancer. The main goals are to see if the combination helps…

This is an early-stage study testing a new experimental drug called SGN-MesoC2 in people with advanced solid tumors that have come back or stopped responding to standard treatments. The main goal is to find a safe dose and see how the body handles the drug. The drug is designed t…

This study is comparing two oral medications, entrectinib and crizotinib, for people with advanced non-small cell lung cancer that has a specific genetic change called ROS1. The main goal is to see which drug is better at delaying cancer growth, especially for patients whose canc…

This is an early-stage study to find a safe dose of a new drug called KFA115, given alone or with an existing immunotherapy (pembrolizumab), for people with advanced cancers that have stopped responding to standard treatments. The main goal is to check for side effects and determ…

This study is testing whether the drugs tucatinib and trastuzumab can help control advanced solid tumors that have specific changes in a protein called HER2. It is for adults with cancers like lung, cervical, or uterine cancer that have spread or cannot be removed by surgery, and…

This was a special access program for the drug capmatinib. It was designed for patients with a specific, advanced form of non-small cell lung cancer who had no other treatment options and could not join a standard clinical trial. The program provided the drug outside of a trial s…

This study is observing how well a combination of the drug Osimertinib and standard chemotherapy works for people with a specific type of advanced lung cancer (EGFR-positive NSCLC) in a real-world setting. It involves 532 adult patients who have already started this specific trea…

This study is testing a combination of two drugs, amivantamab and capmatinib, for people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The first part aims to find a safe and effective dose. The second part will see how well this dose w…

This trial aimed to test a new cell therapy for metastatic non-small cell lung cancer. It planned to use a patient's own tumor-fighting immune cells, genetically edited with CRISPR technology to remove a molecular 'brake' called CISH. The goal was to see if these supercharged cel…

This study is testing whether a targeted pill called alectinib works better than standard chemotherapy to prevent lung cancer from coming back after surgery. It involves patients whose lung cancer has been completely removed and who have a specific genetic marker (ALK-positive). …

This study is testing a new drug called JDQ443, both alone and in combination with other treatments, for patients with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find safe doses and see if the treatments can shrink tumors. It…

This study is testing a new personalized vaccine treatment for people who have had surgery for non-small cell lung cancer. The goal is to see if the vaccine, given with an immune-boosting drug, can train the body's immune system to recognize and attack any remaining cancer cells …

This early-stage study is testing whether combining two drugs, amivantamab and docetaxel, is safe and effective for people with metastatic non-small cell lung cancer that has worsened after standard chemotherapy and immunotherapy. The first part of the study aims to find the righ…

This study is for people with advanced non-small cell lung cancer that has worsened after prior treatments. It aims to test the safety and find the best dose of an experimental drug called MK-3475 when given alongside a standard chemotherapy drug, gemcitabine. Researchers will mo…

This is an early-stage study to test the safety and initial effects of a new drug called PF-08046037. It is being tested alone and in combination with another immunotherapy drug (sasanlimab) in people with advanced or spreading cancers, including lung, head and neck, skin, and pa…

This study is testing an experimental drug called disitamab vedotin for adults with advanced or metastatic solid tumors that have a specific marker called HER2. The trial includes people with head and neck, lung, ovarian, or endometrial cancers who have already tried other treatm…

This early-stage study is testing whether adding a short, focused course of radiation (a 'boost') to a standard immunotherapy drug (durvalumab) is safe and can help control stage III non-small cell lung cancer. The treatment is given after patients finish their initial chemo-radi…

This study is testing new drug combinations for people with advanced solid tumors that have a specific genetic change called KRAS G12C. It focuses on patients with non-small cell lung cancer or colorectal cancer who have already tried standard treatments. The main goals are to fi…

This large, late-stage study is comparing a new two-drug combination (amivantamab + lazertinib) against the current standard single-drug treatment (osimertinib) for people newly diagnosed with a specific type of advanced lung cancer. It aims to see if the combination can better c…

This study aims to understand how the immune system changes in stage III non-small cell lung cancer patients receiving standard treatment. Researchers will observe 45 patients undergoing chemoradiation followed by immunotherapy (durvalumab) to identify immune markers that might p…

This research study aims to learn about the biological features of how chest cancers like lung cancer, thymus tumors, and mesothelioma develop and spread. Researchers will analyze blood, tumor tissue, and other fluids from about 1000 patients to look for genetic markers. The goal…

This study aims to see if providing standardized training to cancer doctors in smaller city and county hospitals leads to better testing and treatment for patients with advanced non-small cell lung cancer. It will follow 1,000 patients to measure if doctors order more recommended…

This study observes 1,200 patients in China with advanced, inoperable non-small cell lung cancer. It aims to understand how patients are actually treated in real-world clinics, what their survival outcomes are, and the financial costs they face. The study collects data from medic…